Clinical Trials Browser

Phase 1/2 × INDUSTRY × Tumor-Agnostic × Clear all

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT06941272 2026-03-13

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms

NCT02908906 2026-03-12

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Phase 1/2 Recruiting

Neoplasms

NCT07213817 2026-03-02

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT06056791 2026-02-27

CaRe

Phase 1/2 Completed

Neoplasms

NCT07276373 2026-02-27

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

Neoplasms

NCT07193511 2026-02-20

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT06818643 2026-02-19

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Phase 1/2 Recruiting

Neoplasms

NCT07335497 2026-02-19

ASCEND

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

Neoplasms

NCT06634849 2026-02-10

An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).

Phase 1/2 Recruiting

Neoplasms

NCT03260023 2026-02-05

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Phase 1/2 Active not recruiting

143 enrolled 24 charts

Neoplasms

NCT06077877 2026-02-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT04260529 2026-01-29

CICILIA

Phase 1/2 Completed

60 enrolled 18 charts

Neoplasms

NCT03872778 2026-01-28

NeoRay

Phase 1/2 Completed

Neoplasms

NCT04145622 2026-01-28

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Phase 1/2 Recruiting

Neoplasms

NCT07112222 2026-01-26

A Study of LM-350 in Subjects With Advanced Solid Tumours

Phase 1/2 Recruiting

Neoplasms

NCT07073534 2026-01-22

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT03096093 2026-01-20

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Phase 1/2 Active not recruiting

Neoplasms

NCT04799054 2026-01-20

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis

NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT05875168 2026-01-12

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT01968109 2026-01-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Neoplasms by Site

NCT07197827 2025-12-24

A Study of YL242 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasms

NCT05731271 2025-12-17

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT05383170 2025-11-28

Catalyst

Phase 1/2 Completed

6 enrolled 11 charts

Neoplasms

NCT05516914 2025-11-28

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT06184035 2025-11-20

Tumorad

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT03363893 2025-11-12

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Phase 1/2 Completed

Neoplasms

NCT05384626 2025-10-30

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Completed

175 enrolled 23 charts

Neoplasms

NCT05118789 2025-10-24

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT02959437 2025-10-21

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Phase 1/2 Terminated

70 enrolled 14 charts

Neoplasm Metastasis

NCT05898399 2025-10-15

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT06796907 2025-10-14

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Neoplasms

NCT04701281 2025-09-18

SYS-CAPLIOX

Phase 1/2 Terminated

Neoplasm Metastasis

NCT06193902 2025-09-03

AERIAL

Phase 1/2 Recruiting

Neoplasms

NCT05220098 2025-08-29

First-in-Human Study of TAK-280 in Participants With Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis

NCT05394103 2025-08-17

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT04717375 2025-08-07

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT05159388 2025-07-08

A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Phase 1/2 Completed

Neoplasm Metastasis

NCT03520075 2025-07-03

Study of ASTX029 in Subjects With Advanced Solid Tumors

Phase 1/2 Completed

192 enrolled 56 charts

Neoplasms

NCT02637687 2025-06-22

SCOUT

Phase 1/2 Active not recruiting

154 enrolled 3 FDA

Neoplasms

NCT06154291 2025-06-22

FIPO23

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT06987500 2025-06-06

A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

Phase 1/2 Recruiting

Neoplasms

NCT04418661 2025-05-29

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Phase 1/2 Terminated

65 enrolled 32 charts

Neoplasm Metastasis

NCT06650566 2025-05-02

Study of LM-299 in Subjects Advanced Malignant Tumors

Phase 1/2 Recruiting

Neoplasms